Subscribe
hynci-istockphoto-com-dollars-cash-
hynci / iStockphoto.com
2 July 2018Americas

AbbVie and Besins to pay FTC $448m in sham litigation case

Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission ( FTC) $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.

More on this story

Americas
Third Circuit under fire over FTC v AbbVie ruling
18 November 2020   The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Alphabet company commit $1bn to collaboration
27 June 2018   AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB